VWA
KPTI icon

VSM Wealth Advisory’s Karyopharm Therapeutics KPTI Stock Holding History

VSM Wealth Advisory’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-133
Closed -$497 – 523
2025
Q1 		$497 Hold
133
– – ﹤0.01% 474
2024
Q4 		$1.35K Buy
+133
New +$1.61K ﹤0.01% 442

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VSM Wealth Advisory's KPTI Position: Q2 2025 in Review

VSM Wealth Advisory sold out of Karyopharm Therapeutics (KPTI) in Q2 2025, closing a stake of 133 shares — an estimated $497 sold.

VSM Wealth Advisory first reported a position in KPTI in Q4 2024 and held it in 2 quarters. The position peaked at $1.35K in Q4 2024. 50 funds tracked by Wall St. Rank hold KPTI as of Q2 2025.

  • VSM Wealth Advisory reported no remaining Karyopharm Therapeutics position as of Q2 2025 after selling out during the quarter.
  • VSM Wealth Advisory sold 133 Karyopharm Therapeutics shares in Q2 2025, an estimated $497.
  • VSM Wealth Advisory first reported a position in Karyopharm Therapeutics in Q4 2024 and held it in 2 quarters.
  • VSM Wealth Advisory's Karyopharm Therapeutics position peaked at $1.35K in Q4 2024.
  • 50 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2025.

Based on VSM Wealth Advisory's 13F filing for Q2 2025, filed 11 Aug 2025.